前列腺立体定向消融放疗加速方案:11天与29天总治疗时间的随机II期研究疗效与毒性
这项加拿大随机II期研究纳入152例中危前列腺癌患者,比较40 Gy/5次隔日(EOD)与每周一次(QW)方案,中位随访62个月。两组晚期QOL、晚期3级以上消化道/泌尿毒性、生化失败及5年OS/CSS均无显著差异,但QW组挽救治疗比例更高(p=0.04),QW组3例出现转移。
要点
- 隔日与每周方案在晚期QOL、晚期3级以上毒性和生化失败方面无显著差异。
- QW组挽救治疗比例显著高于EOD组(4例 vs 0例,p=0.04)。
- QW组有3例出现转移,EOD组无转移;5年OS和CSS两组无差异。
核心结论
- 每周前列腺SABR与隔日方案相比,晚期毒性、QOL、生化失败或PSA动力学无差异。
- 尽管先前报告每周方案急性肠道和泌尿QOL更好,但更新结果未显示晚期终点差异。
- 应告知患者每周SABR较隔日SABR减少短期毒性(原文结尾表述存在笔误,此处按上下文理解)。
研究设计与样本
- 多中心、加拿大随机II期研究,纳入中危前列腺癌男性患者。
- 随机分为40 Gy/5次隔日(EOD)组与每周一次(QW)组,共152例来自3个中心。
- 主要终点为采用EPIC量表评估的急性肠道QOL出现最小临床重要变化(MCIC)的比例。
- 次要终点包括毒性、生化失败(BF)、其他QOL域和挽救治疗率,中位随访62个月。
主要发现
- 晚期QOL变化两组无显著差异;晚期3级以上消化道毒性EOD组1例(1.3%)vs QW组3例(2.7%),p=0.36。
- 晚期3级以上泌尿毒性EOD组5例(6.7%)vs QW组2例(2.7%),p=0.44。
- 生化失败EOD组2例 vs QW组5例,5年失败率3.0% vs 7.2%,p=0.22。
- 挽救治疗EOD组0例 vs QW组4例,p=0.04;QW组3例出现转移。
- 5年OS和CSS分别为95.8%和98.6%,两组无差异(p=0.49,p=0.15)。
关键数值与推荐
- 中危前列腺癌放疗方案:40 Gy分5次,隔日或每周一次。
- 主要终点为EPIC量表急性肠道QOL的MCIC比例。
临床怎么用
- 每周SABR可减少短期毒性,但需注意本研究中挽救治疗比例更高且出现转移病例。
- 隔日与每周方案在晚期毒性、QOL和生化控制方面无显著差异,可与患者个体化讨论选择。
局限性
- 样本量较小(152例),部分终点事件数少,统计效能有限。
- 原文未报告具体MCIC阈值及急性QOL结果数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate stereotactic ablative radiotherapy (SABR) regimens differ in time, dose, and fractionation. We report an update of a multicentre, Canadian randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL), efficacy, and toxicity. METHODS: Men with intermediate risk prostate cancer were randomized to 40 Gy in 5 fractions delivered every other day (EOD) versus once per week (QW). Primary outcome was proportion of patients experiencing a minimally clinically important change (MCIC) in acute bowel QOL using EPIC. Secondary outcomes were toxicity, biochemical failure (BF), other QOL domains, and the rate of salvage therapy. FINDINGS: 152 men from 3 centers were randomized; the median follow-up was 62 months. Results are described for EOD versus QW. Acute bowel and urinary QOL was reported previously. Late changes in QOL were not significantly different between the two arms. There were 1 (1.3%) vs 3 (2.7%) late grade 3 + GI toxicities (p = 0.36) and 5 (6.7%) vs 2 (2.7%) late grade 3 GU toxicities (p = 0.44). Two and 5 patients had BF (5-year failure rate 3.0 vs 7.2%, p = 0.22); 0 and 4 patients received salvage therapy (p = 0.04). 5-Year OS and CSS was 95.8% and 98.6% with no difference between arms (p = 0.49, p = 0.15). 3 patients in the QW arm developed metastases. INTERPRETATION: Although we previously reported that weekly prostate SABR had better bowel and urinary QOL compared to EOD, the updated results show no difference in late toxicity, QOL, BF, or PSA kinetics. Patients should be counseled that QW SABR reduces short-term toxicity compared to QW SABR.
引用
- Alayed Y, Quon H, Ong A, et al. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Radiother Oncol. 2020. PMID: 32416376. doi:10.1016/j.radonc.2020.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。